Johnson & Johnson (JNJ) Stock Forecast & Price Target

$154.22 +1.10 (+0.72%)

Closing price 03:59 PM Eastern

Extended Trading

$154.00 -0.23 (-0.15%)

As of 07:46 PM Eastern

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
9

Buy
9

Based on 18 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 9 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for JNJ.

Consensus Price Target

$170.67
10.66% Upside

According to the 18 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $170.67. The highest price target for JNJ is $215.00, while the lowest price target for JNJ is $150.00. The average price target represents a forecasted upside of 10.66% from the current price of $154.22.

Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

JNJ Analyst Ratings Over Time

Type	Current Forecast 2/11/24 to 2/10/25	1 Month Ago 1/12/24 to 1/11/25	3 Months Ago 11/13/23 to 11/12/24	1 Year Ago 2/11/23 to 2/11/24
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	6 Buy rating(s)	7 Buy rating(s)	5 Buy rating(s)
Hold	9 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$170.67	$174.71	$175.00	$176.14
Forecasted Upside	10.66% Upside	22.98% Upside	14.65% Upside	12.36% Upside
Consensus Rating	Moderate Buy	Hold	Moderate Buy	Hold

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Johnson & Johnson Stock vs. The Competition

Type	Johnson & Johnson	Medical Companies	S&P 500
Consensus Rating Score	2.56	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	11.93% Upside	26,655.44% Upside	13.78% Upside
News Sentiment Rating	Positive News See Recent JNJ News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/3/2025	Guggenheim 2 of 5 stars	Vamil Divan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$162.00 ➝ $166.00	+9.15%
1/28/2025	Barclays 3 of 5 stars	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$159.00 ➝ $166.00	+8.56%
1/24/2025	Argus 2 of 5 stars	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
1/23/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00	+23.49%
1/23/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$175.00 ➝ $163.00	+11.02%
1/23/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$182.00 ➝ $169.00	+15.12%
1/23/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$170.00 ➝ $155.00	+5.58%
1/23/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$166.00 ➝ $152.00	+4.55%
1/23/2025	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$170.00 ➝ $165.00	+13.49%
1/23/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tim Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$160.00 ➝ $159.00	+9.36%
Get the Latest News and Ratings for JNJ and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.
12/11/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$185.00 ➝ $175.00	+19.18%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$190.00	+25.12%
10/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$215.00 ➝ $215.00	+30.70%
7/23/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/23/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$160.00 ➝ $150.00	-2.75%
7/19/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$160.00 ➝ $155.00	+0.27%
7/18/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$161.00 ➝ $171.00	+9.10%
7/18/2024	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$195.00 ➝ $185.00	+18.03%
7/18/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$195.00 ➝ $185.00	+18.38%
4/18/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$169.00 ➝ $170.00	+17.43%
12/1/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$167.00 ➝ $180.00	+16.39%
8/4/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$167.00 ➝ $170.00	-0.42%
7/21/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$175.00 ➝ $180.00	+5.75%
7/21/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$170.00 ➝ $175.00	+3.92%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:47 PM ET.

Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, February 4, 2025. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

Johnson & Johnson reported earnings per share (EPS) of $2.04 for the latest quarter, exceeding the consensus estimate of $1.99, indicating strong financial performance and effective management.
The company has a robust return on equity of 34.35%, which suggests that it is efficient in generating profits from its equity investments, making it an attractive option for investors seeking high returns.
With a quarterly revenue of $22.52 billion, which is up 5.3% year-over-year, Johnson & Johnson demonstrates consistent growth, appealing to growth-oriented investors.
The current stock price is $153.73, which is relatively stable and reflects investor confidence, making it a potentially safe investment in the healthcare sector.
Johnson & Johnson has announced a quarterly dividend of $1.24 per share, translating to an annualized dividend of $4.96 and a yield of 3.23%, providing a steady income stream for dividend-seeking investors.

Johnson & Johnson
Bear Case

Investors should be bearish about investing in Johnson & Johnson for these reasons:

The company’s EPS has decreased from $2.29 in the same quarter last year to $2.04, indicating a decline in profitability, which may concern potential investors.
Johnson & Johnson's payout ratio is currently 74.59%, suggesting that a significant portion of its earnings is being distributed as dividends, which could limit funds available for reinvestment in growth opportunities.
Analysts have mixed ratings on the stock, with some lowering their price targets, which may indicate uncertainty about the company's future performance.
The stock has a beta of 0.52, indicating lower volatility compared to the market, which may not appeal to investors looking for high-risk, high-reward opportunities.
Insider ownership is only 0.16%, which may suggest a lack of confidence from those closest to the company, potentially raising red flags for investors.

JNJ Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $170.67, with a high forecast of $215.00 and a low forecast of $150.00.
: 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last twelve months. There are currently 9 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JNJ shares.
: According to analysts, Johnson & Johnson's stock has a predicted upside of 10.66% based on their 12-month stock forecasts.
: Over the previous 90 days, Johnson & Johnson's stock had 1 upgrade by analysts.
: Johnson & Johnson has been rated by research analysts at Argus, Bank of America, Barclays, Citigroup, Guggenheim, Leerink Partners, Morgan Stanley, Raymond James, Royal Bank of Canada, Stifel Nicolaus, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Johnson & Johnson less than other "medical" companies. The consensus rating score for Johnson & Johnson is 2.56 while the average consensus rating score for "medical" companies is 2.82. Learn more on how JNJ compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NYSE:JNJ) was last updated on 2/10/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Stock Forecast & Price Target